Key result
DOPAL autotoxicity modeling predicts a triphasic cardiac norepinephrine decline in Lewy body diseases, confirmed on PET.
Why the study?
An extended computational model was needed to predict the progression of cardiac sympathetic noradrenergic deficiency in Lewy body diseases and evaluate the effects of genetic predispositions and treatments.
Does a computational model incorporating cardiac sympathetic activation and DOPAL-mediated autotoxicity accurately predict the longitudinal progression of cardiac norepinephrine deficiency and treatment timing effects in Lewy body diseases?
Does a computational model incorporating cardiac sympathetic activation and DOPAL-mediated autotoxicity accurately predict the longitudinal progression of cardiac norepinephrine deficiency and treatment timing effects in Lewy body diseases?
Answers are grounded in this paper and cite their sources.
This computational and empirical study demonstrates that cardiac catecholamine deficiency in Lewy body diseases follows a triphasic progression, suggesting that disease-modifying therapies like MAO inhibitors must be initiated during the preclinical transition from homeostasis to dyshomeostasis (identifiable via 18F-DA PET or skin biopsy alpha-synuclein biomarkers) to substantially delay symptomatic onset.
Background Lewy body diseases (LBDs) feature deficiency of the sympathetic neurotransmitter norepinephrine in the left ventricular myocardium and sympathetic intra‐neuronal deposition of the protein alpha‐synuclein (αS). LBDs therefore are autonomic synucleinopathies. Computational modeling has revealed multiple functional abnormalities in residual myocardial sympathetic noradrenergic nerves in LBDs, including decreased norepinephrine synthesis, vesicular storage, and recycling. We report an extended model that enables predictions about the progression of LBDs and effects of genetic predispositions and treatments on that progression. Methods and Results The model combines cardiac sympathetic activation with autotoxicity mediated by the dopamine metabolite 3,4‐dihydroxyphenylacetaldehyde. We tested the model by its ability to predict longitudinal empirical data based on cardiac sympathetic neuroimaging, effects of genetic variations related to particular intra‐neuronal reactions, treatment by monoamine oxidase inhibition to decrease 3,4‐dihydroxyphenylacetaldehyde production, and post‐mortem myocardial tissue contents of catecholamines and αS. The new model generated a triphasic decline in myocardial norepinephrine content. This pattern was confirmed by empirical data from serial cardiac 18 F‐dopamine positron emission tomographic scanning in patients with LBDs. The model also correctly predicted empirical data about effects of genetic variants and monoamine oxidase inhibition and about myocardial levels of catecholamines and αS. Conclusions The present computational model predicts a triphasic decline in myocardial norepinephrine content as LBDs progress. According to the model, disease‐modifying interventions begun at the transition from the first to the second phase delay the onset of symptomatic disease. Computational modeling coupled with biomarkers of preclinical autonomic synucleinopathy may enable early detection and more effective treatment of LBDs.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (2022) studied Lewy body diseases (including Parkinson disease and pure autonomic failure). Computational modeling of cardiac sympathetic activation and 3,4-dihydroxyphenylacetaldehyde (DOPAL)-mediated autotoxicity vs. Control subjects and model simulations without DOPAL effects or with monoamine oxidase inhibition was evaluated on Progression of myocardial vesicular norepinephrine (NEv) deficiency and 18F-dopamine-derived radioactivity. Computational modeling incorporating DOPAL autotoxicity predicted a triphasic decline in myocardial norepinephrine content in Lewy body diseases, confirmed by serial 18F-dopamine PET imaging.
Synapse has enriched 10 related papers. Consider them for comparative context: